



UAB

Spring 2013

Psychiatry

TAKING INITIATIVE TO CHANGE
TOMORROW



Message from the Chairman

Welcome to this issue of UAB Psychiatry. In this issue, we share with you a few of the many successes of our faculty, staff, and trainees, and highlight a broad spectrum of services we provide and accomplishments of our team. One of the critical mandates when I arrived at UAB was to expand our academic mission, with emphasis on the development of our research mission and extramurally funded grant portfolio. In this issue, we showcase our most recent faculty recruit, Dr. Karen Gamble. Dr. Gamble moved late last year from Vanderbilt, and has rapidly established her laboratory in some of our recently renovated state-of-the-art laboratory space housed in the Sparks Building. As you will read, she is truly a translational scientist focusing on our daily rhythms such as sleep that are often profoundly disturbed in a number of psychiatric conditions. While the core of her research is in rodent models, she maintains an interest in clinical questions such as the impact of the ability of nurses working the late shift to adapt to this artificially imposed change in their body's natural sleep-wake cycle. In addition to introducing Dr. Gamble, we showcase some of the recent research successes of both scientists that I have brought to UAB since my arrival as well as of scientists that have been in the Department longer than my tenure. Hopefully we have captured the excitement that pervades these many laboratories and research teams throughout the Department.

Contemporary Psychiatry departments are often involved in more activities than many are aware. On the other end of the spectrum, I am pleased that we are able to share with you in this issue a few of the services that members of the department provide to patients in our community as well as other outreach programs. UAB Psychiatry has more direct involvement in the community and a stronger public mission than many (if not most) major academic Psychiatry departments around the country. I am especially proud of the extraordinary service and lifetime commitment of one of our faculty members, Foster Cook, to the public mission. One of his programs was in the news a fair amount last fall given local budget pressures, but rest assured that we as a Department, and especially Foster and his wonderful team, continue to do everything we possibly can to provide as much service as possible in his numerous programs throughout our community. I have come to realize that many people are not even aware of some of these activities, or that they are part of UAB Psychiatry. In addition, some readers will know that UAB Psychiatry runs one of the city's Mental Health Centers, under the outstanding leadership of Drs. Jackie Feldman and Bob Savage. One of our newest accomplishments in this sector is the recent funding from the U.S. Department of Housing and Urban Development (HUD) to Harry Findley for grants to provide housing for the homeless mentally ill. We also showcase the outreach efforts of two members of the department: Dr. Francisca MgBodile's work in Nigeria, and Dr. Theo Morgan's work with young people in Birmingham.

This spectrum...from basic studies in mice to this degree of community outreach...all contained within our Department, is part of what makes UAB Psychiatry so great. This issue coincides with my fourth anniversary as the Chair of the Department of Psychiatry at UAB. I appreciate all of the nice feedback we have received from many of you regarding this particular publication, and genuinely enjoy being able to bring you continued news of the many good things the wonderful people in our Department do as part of their work and lives.

James H. Meador-Woodruff, M.D.

Herman E. Drummond Professor and Chair
UAB Department of Psychiatry and Behavioral Neurobiology



Table of Contents

- 1 Message from the Chairman
- 2 Table of Contents
- 3 Through Research and Awareness Comes Understanding
- 7 Clinical Trials
- 8 Fostering Suicide Awareness through the Community
- 9 Changes in Administration
- 10 Changes to Educational Training Programs
- 11 Extending a Helping Hand
- 13 New Faculty
- 15 Discovering the Answers
- 16 Meet Psychiatry's Access Team
- 20 Funding the Future of Research



Psychiatry

SC 560
1530 3rd Avenue South
Birmingham, AL 35294-0017

www.uab.edu/medicine/psychiatry

Editor in Chief
James H. Meador-Woodruff, M.D.

Managing Editors
Jessica L. Dean

Publications
M. Eve Rhea, M.A.

MOOD DISORDERS PROGRAM

**Through
Research and
Awareness
Comes
Understanding**

Psychiatry's Newly Created Mood Disorders Research Program

The newly constructed Mood Disorders Research Program, under the supervision of Dr. Richard Shelton, is a multidisciplinary, cross-campus initiative that provides diagnostic and consultative assessment, educational programming, and partnership to the community. This program marks the development of highly advanced research focused on understanding the causes of depression and bipolar disorder, and the advancement of treatment approaches for these diseases. With community support, university-wide collaboration efforts, and an outstanding clinical research team, the goal of this program is to achieve a Top 10 ranking; therefore, becoming a leader in mood disorders treatment and research efforts in the nation. The Department has already shown strengths in this area, especially in our efforts focused on suicide awareness and prevention. The Department's laboratory models of depression have a goal of identifying promising targets for new treatment development. A strong group of preclinical research laboratories bring innovative new treatments to UAB, most recently with the introduction of repetitive transcranial magnetic stimulation (rTMS) for the treatment of depression. The Department plans further growth and development of patient-based research which will include the expansion of our programs in experimental therapeutics for mood disorders, neuromodulation, translational preclinical investigations, and brain imaging in depression and bipolar disorder. Dr. Shelton's research not only focuses on the development of new experimental therapeutics, but strives to identify new targets for treatment and prevention of serious mental illnesses.



New Leadership for a New Program

Richard C. Shelton, M.D., has been recruited to join the Department as Professor of Psychiatry, Vice Chair for Research, and as the Director of the UAB Mood Disorders Program. Dr. Shelton will oversee the development and expansion of UAB's recently established Mood Disorders Program. He has been an active researcher, clinician, and teacher at both Vanderbilt University and UAB. Dr. Shelton and his colleagues have had more than 100 funded research studies from the National Institute of Health (NIH), private foundations of industry, and numerous Federal agencies including 39 Federal grants. Dr. Shelton is internationally respected and highly regarded for his many contributions to our understanding of depression. He has been, and remains at the forefront of developing novel and innovative treatment approaches for mood disorders with a focus on depression. His research has been supported throughout his career including the publication of more than 250 scholarly reports. He has more than 340 publications; comprising of original research reports, reviews, commentaries, and book chapters. He has served on NIH study sections for many years and currently is the chair of the Adult Psychopathology and Disorders of Aging review group. As the leader of this translational program, he will bind together the Department's areas of current strengths under one roof, and lead the effort to expand our Mood Disorders Program.

Recent Hires

Dr. Shelton's research efforts are supported by a dedicated and well-trained research staff. In addition to regulatory and administrative expertise, The Office of Psychiatric Clinical Research provides quality patient care in the context of research studies. The work of our research team is focused on experimental therapeutics and the identification of testing and treating serious mental illnesses. The research staff is responsible for coordinating studies, recruiting and screening subjects, sample analysis, and interfacing with collaborative institutions. If you have questions or would like to inquire about the Mood Disorders Research Program, please call 205.934.2484.

"We have a world-class research team capable of executing even the most complex of clinical research studies. I feel very fortunate to work with such an outstanding team," says Dr. Shelton.

Expansion of Clinical Research Space

The Departmental clinical research program, including the UAB Mood Disorders Program, has moved into newly renovated state-of-the-art research space on the 10th floor of the Sparks Building on the corner of 7th Avenue South and 18th Street South. This will dramatically increase the space available for the program and accommodate the recent expansion of the Departmental clinical research enterprise. This area comprises 11,767 square feet of space, which includes 31 faculty and staff offices, a fully appointed exam room, lab space for collecting and processing research samples, two well-equipped conference rooms (which include videoconferencing capabilities), dedicated testing rooms, a patient waiting area, and a break room. This move also places the clinical research program in close proximity to the basic research labs of the Department, which will facilitate future translational research.



ONGOING SUMMARY OF RESEARCH

Depression, Inflammation, and Obesity


The UAB Mood Disorders Program has launched a series of studies, along with Dr. Barbara Gower with the UAB Nutrition and Obesity Research Center, which aim to investigate the link between obesity and risk for depressive disorders. There is a large amount of research that indicates a strong relationship between depression and obesity. Studies show, lean people with depression are much more likely to become depressed than the general population. However, the reverse also holds. Obese, non-depressed individuals are much more likely to become depressed than non-obese individuals. Although the relationship between the two is established, the causal factors are unknown.

Recent data indicate that both physical and psychological stress increase the local release of the cytokine interleukin-1 (IL-1) from stroma-vascular cells in peripheral, but not abdominal fat. This results in a release of fatty acids and an inhibition of triglyceride synthesis in peripheral fat, such as that contained in subcutaneous tissue. A similar reaction does not occur in abdominal fat tissue, also known as visceral fat. Repeated stressors over time result in a shift of fatty acids from non-visceral to visceral fat stores. It is well-known that visceral fat is associated with much of the adverse health effects of obesity. Our current hypotheses is that life stressors that precipitate depressive episodes may contribute to visceral fat, and that repeated depressive episodes act like stress and shift fat to the abdomen. The release of cells associated with this type of fat is associated with an increased risk for cardiovascular disease, type-2 diabetes, and other metabolic conditions.

How does this link to depression?

Dozens of studies have shown an increase in blood cytokines in depressed patients. Cytokines are known as signaling molecules for intercellular communication. In addition, the administration of inflammatory factors such as interferon (IFN) therapy for diseases, such as hepatitis and several types of cancer is known to induce depression in a high proportion of patients. It is likely that the cytokine response of visceral fat may increase the risk for depression, which could explain why obesity predicts future episodes of depression. It is also likely that repeated bouts of depression increases visceral fat and inflammatory cytokine response. This, in turn, may contribute to relapse of depression and, ultimately, chronic illness.

Our recent data supports this view. Compared to obese controls and lean depressed controls, people with combined obesity and depression show a marked elevation in several inflammatory factors. The Mood Disorders Program is now pursuing research to determine whether this interaction is due primarily to visceral fat. Future research will include diet and exercise interventions for chronic depression and the use of anti-inflammatory medications to treat depression. The Department is also planning to study visceral fat in children, and the possible subsequent increase in the risk for depression. If successful, this program of research could radically transform medical practice and provide new avenues for treatment and prevention of depressive disorders.

A photograph of a group of people in a meeting, overlaid with a blue tint. The image shows several individuals, including a man in a suit and a woman, engaged in a discussion around a table.

Recent research studies have focused on testing new treatments for depression, treatment resistant depression, and bipolar disorder. These include:

Depression

Testing the Effectiveness of Medications that Target the Glutamate-NMDA Receptor System. Patients with major depressive disorder (MDD) that do not sufficiently respond to standard treatments. About 70% of depressed people do not have adequate responses to the most commonly prescribed medications for depression. Further investigation is critical. This study is testing a possible new treatment for depression that has not responded adequately to antidepressant medications.

Low Field Magnetic Stimulation (LFMS) for Depression.

There is emerging evidence that prolonged exposure of the brain to a low field strength magnetic field may rapidly relieve depression. This study will test this very novel approach for depressed patients.

The Effectiveness of Ketamine for Depression and

Suicidal Ideation. Recently, low doses Ketamine, a type of anesthetic medication, have been shown to alleviate depression symptoms with greater efficacy and speed compared with standard medications. There are two different studies currently conducted to assess the effectiveness of this approach both acutely and in a sustained fashion on depression and suicidal thoughts. Recent studies have demonstrated that IV infusions of ketamine, an NMDA-receptor antagonist, at sub-anesthetic doses (0.5mg/kg), produce antidepressant effects within hours of administration.

A Comparison of Lithium versus Paliperidone (Combined with SSRI) for Patients with Depression and Suicidal Ideation. This study is comparing the benefits and harms of two treatments; Lithium or Paliperidone, combined with selective serotonin reuptake inhibitor (SSRI) antidepressants, for persons with depression and associated suicidal ideation. This project is supported by the American Foundation for Suicide Prevention.

“About 70% of depressed people do not have adequate responses to the most commonly prescribed medications...”

Bipolar Disorder

Lithium or Quetiapine for the Treatment of Bipolar

Disorder. This study, funded by the Agency for Health Quality and Research, is comparing both benefits and harms of two commonly-used medications for bipolar disorder.

Ramelteon as an Acute and Maintenance Medication for Bipolar Disorder.

Circadian misalignment, such as phase delayed sleep, is commonly found in persons with bipolar disorder. These two studies will assess the potential effectiveness of the medication Ramelteon, which stimulates melatonin-1 and -2 receptors, as both an acute and maintenance treatment for bipolar disorder.

Bioenergetic and Mitochondrial Dysfunction in Bipolar


Disorder. There is growing evidence of increased oxidative stress, the presence of toxic oxygen-containing molecules in the cells of people with bipolar disorder. However, the cause of this problem is unknown. A collaboration with Dr. Aimee Landar of the UAB Center for Free Radical Biology, will determine if bipolar disorder is a condition involving mitochondrial dysfunction, buffering, or elimination of oxidative stress molecules. If successful, this project could provide new targets for treatment for this serious illness.



FOSTERING SUICIDE AWARENESS THROUGH THE COMMUNITY

Walking Towards Prevention

The American Foundation for Suicide Prevention (AFSP) is the leading non-profit organization dedicated to understanding and preventing suicide through research, education and advocacy. According to Dr. Cheryl McCullumsmith, Assistant Professor, Division Director for Hospital Psychiatry, and President of the AFSP Alabama Chapter, suicide is the 10th leading cause of death in the U.S., and the fourth leading cause of death for adults under the age of 65. AFSP sponsors the annual Out of the Darkness community walks that raise funds for much needed outreach and education within the community. For the 5th consecutive year, UAB Psychiatry participated in the Birmingham Out of the Darkness walk that was held on Sunday, November 4th, at Heardmont Park in Pelham, Alabama. In 2012, AFSP hosted several walks throughout the state with over \$190,000 raised and more than 2,500 people participating. Team "UAB Psychiatry" was one of the top five ranked teams with registered participants including faculty, staff, residents, and family members. The Alabama Chapter originated in 2006, with its first Out of the Darkness walk in Birmingham. Since that time, the Alabama Chapter has received awards for Top Chapter in the Nation in Excellence and Education Outreach. The Birmingham walks have continuously ranked in the top ten annual community walks nationwide, and have provided funds for many important suicide prevention programs within our state, including research grants for our Department. If you would like to participate in a future walk or if you would like to learn more about AFSP, please visit their website at www.afsp.org/alabama.




Changing the Conversation:

Send Silence Packing

Psychiatry recently participated in the Send Silence Packing event that came through Birmingham for the first time on October 29, 2012. Located on the UAB campus green, this was the first Send Silence Packing event to come through the South, and is sponsored by the UAB Active Minds Chapter. 1,100 backpacks were laid out across the campus green, each backpack symbolizing a college-aged student who completes suicide each year. Active Minds collects backpacks, letters and personal stories in memory of loved ones impacted by suicide. A.T. Helix is the founder and president of the UAB Active Minds Chapter. She is an undergraduate and researcher in the laboratory of Dr. James Meador-Woodruff. Active Minds is an organization that focuses on mental health issues affecting college-aged youth. The Active Minds program travels to different universities throughout the country to promote suicide awareness, prevention and is "a national organization whose goal is to change the conversation about mental health," says Helix. Active Minds has two goals through these Send Silence Packing Events. "One is for students to understand that there are people willing and able to help them if they are depressed or contemplating suicide; the second is for people to recognize the signs in their friends and to reach out to them," says Helix. If you would like to learn more about Send Silence Packing including the future campus schedule, please visit their website at <http://sendsilencepacking.org/>.

“Active Minds
collects backpacks,
letters and
personal stories in
memory of loved
ones impacted by
suicide.”



CHANGES IN ADMINISTRATION

Department Names New Vice Chairs



Jackie Feldman, M.D.

Vice Chair for Clinical Affairs
Jacqueline Feldman, M.D., the Patrick H. Linton Professor in the Department of Psychiatry, has been appointed to Vice Chair for Clinical Affairs. Dr. Feldman has served for

a number of years as the Director of the UAB Division of Public Psychiatry which serves as a blanket for both the UAB Mental Health Center and Beacon Parkway Substance Abuse program, including the UAB Treatment Alternatives for Safer Communities (TASC). Dr. Feldman has distinguished herself as a tireless and passionate advocate for all of the patients the Department serves, especially the most vulnerable with severe mental illness. She received her Medical Degree from the University of Texas-Houston Health Science Center, and completed her Internship and Residencies from Duke University Medical Center in 1987. Dr. Feldman was also recently named Medical Director for the Center for Psychiatric Medicine, and has assumed this role from Dr. Ray Thweatt.



Lee Ascherman, M.D., MPH

Vice Chair for Education and Training

Lee Ascherman, M.D., MPH, is the Department's Vice Chair of Education & Training. Dr.

Ascherman is the Division Director

of the Child and Adolescent Psychiatry Program, Chief of Service for Child and Adolescent Psychiatry and The Children's Hospital of Alabama. He is a child and adolescent psychiatry Steering Committee member for the American Board of Psychiatry and Neurology, and Secretary and Chair elect for The Board on Professional Standards of the American Psychoanalytic Association. He also serves as an Associate Editor for the Journal of the American Psychoanalytic Association. Dr. Ascherman earned his Medical Degree from Case Western Reserve University, and completed his internship and residencies with Georgetown University Hospital in 1986. He also received the 2011 UAB President's Diversity Award for a Faculty Member, honoring his tireless efforts to promote diversity in the Division of Child and Adolescent Psychiatry and his exemplary track record of recruiting, training, and retaining one of the most ethnically and racially diverse groups within the entire University.



Nathan Smith, M.D.

Vice Chair for Administrative Affairs
Nathan Smith, M.D., is a professor of psychiatry, Vice Chair for Administrative Affairs, and the Assistant Dean for Students and Admissions at the UAB School

of Medicine. He received his undergraduate degree at Samford University and then completed his Masters of Divinity degree from the Southern Baptist Theological Seminary in Louisville, Kentucky. Dr. Smith subsequently completed his Medical Degree from the UAB School of Medicine, and his residency in psychiatry at Dartmouth-Hitchcock Medical Center in Hanover, New Hampshire. Within the Department, Dr. Smith previously served as Vice Chair for Education and Training, Director of the Psychiatry Residency Training Program, and the Director of the Psychiatry Medical Student Clerkship. Currently, his area of care is focused on UAB's Medical School, and The Office of Medical Student Services where he oversees the admissions process for the School of Medicine, and is a member of the team that supports medical students in their academic and professional development.



Richard Shelton, M.D.

Vice Chair for Research

Richard Shelton, M.D., is the Department's new Charles B. Ireland Professor of Psychiatry and Vice Chair for Research. Dr. Shelton obtained his Medical

Degree from the University of Louisville in Louisville, Kentucky in 1979. He was named Chief Resident during the completion of his residency at the Massachusetts Mental Health Center, now the Longwood Program. After residency, he served as a research fellow at the National Institutes of Mental Health Intramural Program in Washington, D.C., before accepting a faculty position at Vanderbilt University in 1985. He became the James G. Blakemore Research Professor and Vice Chair for Clinical Research in the Department of Psychiatry and Professor in the Departments of Psychology and Pharmacology as a faculty member with Vanderbilt University. Dr. Shelton joined the faculty of the Department of Psychiatry and Behavioral Neurobiology at UAB in February 2012, and heads the newly formed Mood Disorders Research Program.



CHANGES TO EDUCATIONAL TRAINING PROGRAMS

Department Names New Vice Chairs

New Training Director



Laura Montgomery-Barefield, M.D., has been named Residency Program Training Director.

Dr. Montgomery-Barefield has served as the Associate Training Director for several years, and stepped into the role of Residency Program Training Director in 2011. Dr. Montgomery-Barefield transitioned into this position from Dr. Daniel Dahl, who previously served in this role for nearly 10 years. Dr. Montgomery-Barefield is an Associate Professor with the Division of Child & Adolescent Psychiatry, and has clinical interests in ADHD, mood disorders, psychotic disorders, and family centered psychiatric treatment that focuses on home and parenting issues. She graduated from the University of Texas, Medical Branch School of Medicine in 1990, and subsequently completed her internship, residency, and fellowship. As an Associate Residency Training Director, she has mentored clinicians and future leaders in the field of psychiatry. Dr. Montgomery-Barefield has done an excellent job developing, growing, and improving the quality of our general residency

"I feel that this is the last formal education experience for residents and it is important to make sure they are prepared not only with medical knowledge, but also with some idea of how they will contribute to society through their psychiatric practice. I think we all have a duty to leave our "footprint" in the field of psychiatry and make this field better than it was when we came into the profession. The Department's program is in a great position for continued resident growth. UAB has a very strong clinical portfolio and our residents have experience in a number of clinical settings due to the Department's residency training. I want to continue to help the residents to become not only great psychiatrists, but also strong leaders and educators in medicine."

- Dr. Montgomery-Barefield

program as an Associate Training Director, and will continue to further the Department's residency program as the Training Director. The Department congratulates Dr. Montgomery-Barefield on her promotion, and is confident in her ability to train and educate the next generation of psychiatrists by ensuring they receive a solid educational foundation within a dynamic field.

New Assistant Training Directors



With Dr. Montgomery-Barefield's appointment as Residency Program Director, two new Assistant Training Directors have been named to assist her with future endeavors. Drs. Andrea Dickens (*top*) and Vinita Yalamanchili (*bottom*) have agreed to serve as Assistant Training Directors for the General Psychiatry Residency Program. Dr. Dickens is an Assistant Professor with the Consult & Liaison Division, and is focused on emergency psychiatric

care in the UAB Emergency Room. Dr. Yalamanchili is also an Assistant Professor with the Division of Child & Adolescent Psychiatry, and primarily practices at The Children's Hospital of Alabama. Assistant Training Directors are responsible for policy and curriculum development, as well as resident recruitment. The ACGME is consistently developing new rules for medical education, and it is the responsibility of the Assistant Training Directors to become familiar with any new policies or procedures, and ensure their implementation into the Education Programs. The Department welcomes Drs. Dickens and Yalamanchili, and congratulates them on their promotions.

Continued Accreditation for Residency Training Programs

The Accreditation Council for Graduate Medical Education (ACGME) has approved continued accreditation status for the General Resident, Geriatric, and Child/Adolescent Training Programs. The ACGME Residency Review Committee (RRC) examined the Specialist Site Visitor Representatives' reports and approved continued accreditation status for all three residency programs. The General Residency and the Geriatric Fellowships received five years, and the Child/Adolescent Fellowship received four years of

accreditation. The ACGME has also approved the expansion of the child and adolescent residency program from 6 to 8 total residents based on recognition of the program's ability to provide an array of training experiences. The ACGME is a private, nonprofit and professional organization that has defined and developed accreditation standards using over twenty specialty evaluation committees, Residency Review Committees. Established in 1981, the ACGME strives to improve health care by enhancing and assessing the quality of resident education. Dr. Laura Montgomery-Barefield, Director of the General Psychiatry Residency Program would like to thank all of the residents and faculty who helped make this site visit successful.

Proposed Psychosomatic Fellowship

The Education and Training offices have proposed the development of a new UAB Psychosomatic Medicine Fellowship Program that will provide training in the psychiatric subspecialty of psychosomatic medicine (consultation-liaison psychiatry) that has not been previously been available at UAB. If approved by the ACGME, the Psychosomatic Fellowship offers care for patients with medical, surgical, or obstetric conditions who also have preexisting psychiatric diagnoses or have developed psychiatric conditions while undergoing treatment. This fellowship not only offers continuous care to patients, but helps residents advance their skills in providing consultation in medical and surgical settings becoming knowledgeable and compassionate physicians with unique expertise in diagnosis and treatment. With a little over 50 psychosomatic fellowships offered in the county, UAB Psychiatry hopes to begin internal recruitment in July 2013. The psychosomatic fellowship will be under the direction of Dr. Wendell Bell, Assistant Professor in the Consult & Liaison Division of Psychiatry.

Training Offices Move to Volker Hall

The Psychiatry Education and Training Office have moved to Volker Hall. For the past 5 years, the Residency Training Program was located at the Eye Foundation Hospital on the corner of 18th Street South and University Boulevard. Since this time, the Department's outpatient clinics and the education programs have continued to grow and expand, creating a need for space. Numerous faculty, resident, and training offices now reside in Volker Hall on the corner of University Boulevard and 16th Street South.



EXTENDING A HELPING HAND

Continued Endeavors of the Child and Adolescent Program

The UAB Division of Child and Adolescent Psychiatry not only provides quality care to the children of Alabama but excellent training to its Fellows through consistent clinical care and proven teaching methods. We are continuously measuring and improving our systems to enhance the patient and family experience and the outcomes of care we deliver. Through a longstanding affiliation with The Children's Hospital of Alabama, a unique system of care has been established between the two institutions to benefit patients and their families. We value our ability to partner with parents and family members in the care of their children, and this partnership is the keystone of quality patient care. We are committed to achieving and maintaining a standard of excellence in all we do. First and foremost, we consistently strive to make the patient experience a model of quality care through advanced treatment, compassionate support and full family participation and communication.

The Division provides consultation services for children and adolescents in the Emergency Departments at UAB and The Children's Hospital of Alabama,

pediatric inpatient services, and outpatient care. There are 35 acute inpatient beds including a nine bed child unit, and additional units for younger and older adolescents. Inpatient and emergency room consultations may be for children and adolescents facing adaptive challenges based on serious medical illness, or for those with psychiatric illness who find themselves challenged with acute or chronic medical illness. The Department provides diagnostic evaluations and ongoing treatment at two busy outpatient clinics. The outpatient clinics serve children of all ages with a range of challenges including mood disorders, psychotic illness, Attention Deficit Disorder, Post Traumatic Stress Disorder and other anxiety disorders, developmental disorders, and learning disorders. Included among outpatient services are specialty clinics for Autism, initial onset of severe mental illnesses, the Engle Therapeutic School, and the Department of Mental Health Child and Adolescent Inpatient Unit. The Sparks Clinic, also anchored with the UAB Psychiatry, is strongly affiliated with the UAB Child and Adolescent Psychiatry Fellowship. All fellows rotate through the Sparks Clinic to gain additional experience in early intervention with higher risk infants, toddlers and young children with development disorders.

These services would not be complete without the assistance from the Department's Fellows. This Fellowship began in 1995 when 6 fellows completed the program, and expanded with approval from the Accreditation Council of Graduate Medical Education (ACGME) to 8 fellows in 2011. This two year program offers subspecialty training in child and adolescent psychiatry to general psychiatrist wishing to pursue a career with children. To date, the program has graduated 34 child and adolescent psychiatrists who have helped to diminish the national shortage of child and adolescent psychiatrists. Most have stayed in the region, providing services in the public, private and academic sectors. The Fellows rotate through all of the clinical sites of the Division where they are provided learning opportunities in inpatient and outpatient care,

acute and long-term treatment, diagnostic evaluations, psychopharmacology, psychotherapy, and group therapy. The Fellowship also has strong affiliations with the Jefferson County School System and the Family Court of Jefferson County. As part of the program's training protocol, the fellows are assigned to a Jefferson County school where they serve the entire school year as consultants to the teachers and administrative staff. The fellows also provide consultations for individual adolescents at the request of the Family Court. Research is also a growing component of the Division's activities. In addition to pharmacologic research and studies of mood disorders in children and adolescents, plans are also underway to research brain activity in adolescents presenting with early psychotic disorders using functional magnetic resonance imaging (MRI) studies.

The Engle Therapeutic School

The Engle Therapeutic School is a member of the Alliance of Psychoanalytic Schools with over 40 years history of psychoanalytically informed education and treatment of children and adolescents from the greater Birmingham area.

The mission statement of the school reads: *The Engle Therapeutic School provides children and adolescents with a school environment that facilitates emotional adaptation and growth so that each student can academically achieve at the leading edge of their ability.*


The school is composed of four classrooms of approximately eight students: a high school, junior high, grade school and preschool classroom; serving children ages 2 to 21 years of age. Many of the children have experienced significant problems with psychological adjustment, family turmoil, and have histories of neglect, abuse, or medical trauma. Lee Ascherman, M.D, MPH, and Headmaster for the Engle School, states "the goal of each classroom is similar but individualized based on the developmental level of each student. Every classroom strives to create an environment in which students can grow and develop in a climate sensitive to their internal and interpersonal worlds while maintaining intellectual and academic growth." Treatment is shaped by the child's individual needs and capacities including individual psychotherapy or psychoanalysis. All students participate in a group therapy, individual counseling, and numerous therapeutic sessions including Hand in Paw animal-assisted therapy and the Therapeutic Equestrian Program. In affiliation with the UAB Division of Child and Adolescent Psychiatry, parental guidance or family therapy is available to the families of every student. The



Engle Therapeutic School has close affiliations with almost all public school districts in the region including the Birmingham City School District, the Jefferson and Shelby County School Districts, and most independent suburban school districts.

The Engle Therapeutic School retains diversity among both the student and faculty populations. In 2010, the Division of Child and Adolescent Psychiatry was awarded the University's Diversity Award for its promotion of diversity among the faculty, fellows, and staff; reflecting the population served. This same year, the Engle Therapeutic Preschool was recognized as a Program of Excellence by the Association for Child Psychoanalysis. In 2007, the Engle Therapeutic Preschool was also awarded the Distinguished Program of the Year Award above the various programs for children in greater Birmingham area by Child Care Resources. Child Care Resources is a non-profit organization that promotes strong, developmentally attuned child care options for a particular region. If you have any questions about this program or would like to support their efforts please contact Shelley Moreno, Program Supervisor, at (205) 975-4537 or moreno@uab.edu.

“The DMH School provides each student with an appropriate, individualized education program based on his or her particular needs and future education plans.”




Department of Mental Health Unit

Since October 2010, the Alabama Department of Mental Health (DMH) has located their adolescent unit from one of the state hospitals, to UAB Hospital, providing excellent care while offering the Fellows in Child and Adolescent Psychiatry the opportunity to work with severely troubled adolescents in a long-term setting. The DMH Adolescent Commitment Unit is a ten bed unit providing psychiatric stabilization services for adolescents ages 12-18. Led by Medical Director Dr. Sam Rubin, the unit serves adolescents who, as a result of mental illness, have been committed to state custody by a juvenile court for posing a threat of substantial harm to themselves or others. This unit strives to provide a safe and supportive environment, individualized treatment plans, and interdisciplinary treatment team assessments for patients and their families. Treatment team members include board-

certified child and adolescent psychiatrists, a child and adolescent psychologist, social workers, nurses, teachers, and occupational/recreational/art therapists. Services provided by the unit include daily individual therapy, twice-weekly group therapy, occupational and recreational therapy, and weekly art, music, and animal therapy. Each adolescent also attends our SACS-CASI accredited education program for 6 hours each weekday. The DMH School provides each student with an appropriate, individualized education program based on his/her particular needs and future education plans. Throughout the discharge process, the treatment team works closely with community service providers in order to ease the adolescent's transition back into the community and to ensure that the transition does not result in any interruption of needed services.

NEW FACULTY



Andrea Dickens, M.D.

Assistant Professor

Andrea Dickens, M.D., has joined the Department as an Assistant Professor with the Consult and Liaison Division. Dr. Dickens has also assumed the role of Associate Training Director for the General Psychiatry Residency Program under the direction of Dr. Laura Montgomery-Barefield. She completed her undergraduate education in Biology from Arkansas Tech University and received her Medical Degree from the University of Arkansas for Medical Sciences in Little Rock, Arkansas. Dr. Dickens completed her psychiatry residency with the UAB Department of Psychiatry where she served as Chief Resident, and will continue to focus on emergent psychiatric services in the UAB Emergency Department. Dr. Dickens offers a wealth of wisdom, and the Department congratulates her on her faculty appointment.



Wendell Bell, M.D., MBA

Assistant Professor

Wendell Bell, M.D., MBA, has joined the Department's faculty as an Assistant Professor in the Consult and Liaison Division. Dr. Bell earned his Medical Degree from the Medical College of Wisconsin and completed his residency at Sheppard and Enoch Pratt Hospital in Baltimore, Maryland. He sub-specializes in medical, surgical, and obstetric consultations at the request of an attending physician, and will assist with electroconvulsive therapy (ECT) services. Upon approval, Dr. Bell will also lead in the development of a new psychosomatic medical fellowship that should begin recruitment in July 2013. The Department welcomes Dr. Bell as a member of the faculty.



Deina Nemiary, M.D., MPH

Assistant Professor

Deina Nemiary, M.D., MPH, has joined the faculty as an Assistant Professor with her appointment in the Consult and Liaison Division. Dr. Nemiary obtained her Medical Degree from the University of Khartoum in Sudan, Africa, and her Master's of Public Health (MPH) from

the University of Illinois at Springfield. She completed her psychiatry residency at Morehouse College in 2012, and recently received a prestigious American Psychiatry Association Minority/SAMSHA Fellowship. Dr. Nemiary is interested in pursuing a career in clinical research with a special interest in mental health disparities among racial/ethnic minorities, and one day hopes to promote this cultural education among Medical Students and Residents. UAB Psychiatry welcomes Dr. Nemiary to the Department.



Kira Fonbah, M.D.

Assistant Professor

Kira Fonbah, M.D., was recently named an Assistant Professor in the Division of Child and Adolescent Psychiatry. After graduating from the UAB School of Medicine, she completed her general residency training with UAB Psychiatry, and recently completed her fellowship in child and adolescent psychiatry. She currently serves a young adult patient population at the Children's Hospital of Alabama, as well as UAB Psychiatry. Dr. Fonbah has a special interest in cross-cultural perspectives of child development, and hopes to develop a specialty service with college-aged adolescents and young adults. The Department welcomes Dr. Fonbah to UAB Psychiatry.



Miriam Sevilla Saez-Benito, M.D.

Assistant Professor

Miriam Sevilla Saez-Benito, M.D., has joined the Department's faculty as an Assistant Professor in the Division of Child and Adolescent Psychiatry. She received her Medical Degree from the University of Granada, Granada, Spain, and completed her general psychiatry residency training at Jamaica Hospital Medical Center in Queens, New York. Dr. Sevilla completed her child psychiatry residency at UAB, serving as Chief Resident for the 2011-2012 academic year. She cares for patients at UAB and The Children's Hospital of Alabama Emergency Department. Fluent in Spanish, Dr. Sevilla seeks to educate parents in the Spanish-speaking community about mental illness and hopes to improve their access to services. The Department congratulates Dr. Sevilla on her faculty appointment.



Sang-wahn Koo, M.D.

Assistant Professor

Sang-wahn Koo, M.D., has joined the Department as an Assistant Professor in the Division of Child and Adolescent Psychiatry. Dr. Koo graduated from Yonsei University

School of Medicine in Seoul, South Korea. He then completed his general psychiatric residency at Griffin Memorial Hospital in Norman, Oklahoma, and child and adolescent psychiatric fellowship at Washington University in St. Louis, Missouri. Dr. Koo's clinical interests are in ADHD, Autism, mood disorders, and psychotic disorders. Dr. Koo is an excellent addition to the faculty, and the Department welcomes him to UAB Psychiatry.




Ross Grimes, Ph.D.

Assistant Professor

Ross Grimes, Ph.D., has joined the UAB Department of Psychiatry as an Assistant Professor in the Division of Child and Adolescent Psychiatry. Dr. Grimes received his

undergraduate degree in Psychology from Georgetown University, followed by his graduate degree and Ph.D. in Psychology from The University of Alabama, School of Medicine. He then completed his internship and a post-doctoral fellowship at UAB. He currently serves as the Clinical Director for the Alabama Department of Mental Health Adolescent Unit at UAB, and his clinical interests are in severe emotional and behavioral disorders and residential and inpatient treatment of children and adolescents. In addition to clinical work, Dr. Grimes has research interests in the use of restraint and seclusion with children and will be participating in medical student and resident/fellow teaching. UAB Psychiatry gladly welcomes Dr. Grimes to the Department.



Ilan Kerman, M.D., Ph.D.

Assistant Professor

Ilan Kerman, M.D., Ph.D., has joined the Department as an Assistant Professor in the Division of Psychiatry and Behavioral Neurobiology. Dr. Kerman is a

graduate of the Medical Scientist Training Program at the University of Pittsburgh where he earned his Ph.D. in Neuroscience. He completed his post-doctoral training at the University of Michigan, and was then appointed as a Research Investigator at the Molecular and Behavioral Neuroscience Institute at Michigan. Dr. Kerman's research focuses on the somatic manifestations of depression and anxiety, as well as the pathophysiology and the medical comorbidity of mood disorders. In

addition to his research efforts, Dr. Kerman is active in the educational mission of the Department lecturing in undergraduate neuroscience classes and medical student seminars. UAB Psychiatry welcomes Dr. Kerman as a member of the Department's faculty.



Merida Grant, Ph.D.

Assistant Professor

Merida Grant, Ph.D., was recently named an Assistant Professor in the Division of Psychiatry and Behavioral Neurobiology. She received her undergraduate

degree in Psychology from Temple University, followed by her graduate degree and Ph.D. in Psychology from Duke University. She pursued postdoctoral training at Western Psychiatric Institute and Clinic in Pittsburgh, Pennsylvania, where her work focused on the psychology and biology of the recovery from depression. Dr. Grant comes to us from the Department of Psychology at Vanderbilt University. Her work currently focuses on the effects of the anterior cingulate in the cognitive control of mood and negative cognitions. Dr. Grant has integrated several diverse fields in the pursuit of her research, including cognitive and emotional psychology, neuroendocrinology, and functional brain imaging. Dr. Grant offers the Department an array of insight, and we welcome her to UAB Psychiatry.




Sarah Clinton, Ph.D.

Assistant Professor

Sarah Clinton, Ph.D., has been joined the Department as an Assistant Professor with the Division of Psychiatry and Behavioral Neurobiology. Dr. Clinton obtained her undergraduate degree

in Neuroscience at the University of Pittsburgh in 1999, and completed her Ph.D. and postdoctoral training at the University of Michigan in 2004. Dr. Clinton received a K99-R00 Pathway to Independence award from the National Institute of Mental Health (NIMH) before moving to the Birmingham area in January 2011 to join the Department. She is also a faculty member with the Comprehensive Neuroscience Center. Dr. Clinton's research program focuses on neurodevelopment and the genetic, biological, and environmental factors that interact to shape emotional behavior, and how perturbed brain development may lead to psychiatric disease. The Department is delighted Dr. Clinton has joined the Department's research efforts.



DISCOVERING


THE ANSWERS

Paving the Way in the Treatment of Schizophrenia

Despite the occasional reference to schizophrenia in the media, schizophrenia may be the most misunderstood psychiatric illness to the general public. In many ways, schizophrenia is the most serious of all psychiatric illnesses affecting nearly 1% of the population. Many people confuse DID (Dissociative Identity Disorder or Multiple Personality Disorder) with schizophrenia. In fact, schizophrenia is not associated with many different personalities, but rather one personality. Schizophrenia does not discriminate, but instead affects all socioeconomic segments and populations. More financial and community resources fund the care and treatment of schizophrenia than any other medical illness. Symptoms include auditory hallucinations often called "voices," delusional beliefs,

paranoia, withdrawal, lack of decision making skills and motivation, and decrease in eye contact and/or facial expression. Patients suffering from schizophrenia rarely exhibit all of these symptoms, but multiple symptoms must be present in order to diagnosis a patient with schizophrenia. Treatment helps to alleviate many symptoms, but most people cope with these often debilitating symptoms throughout their lives. The Department's extensive research teams and laboratories are continuously conducting research to better understand the causes of schizophrenia.

**Schizophrenia affects nearly
2 million people in the U.S., and
50 million people worldwide.**



NIH Grants Fund Research

Drs. James Meador-Woodruff (left) and Robert McCullumsmith (right) have received two recent National Institute of Health (NIH) grants totaling \$3.9 million to study the causes of schizophrenia and to develop new targets for treating the illness. These studies involve cutting edge methodologies, including laser capture micro dissection and advanced proteomics techniques, permitting the investigators to ask and answer the largest possible questions related to the causes of schizophrenia. With these techniques, Drs. Meador-Woodruff and McCullumsmith will probe for abnormalities of glutamate neurotransmission in the frontal cortex region of brains from deceased subjects with schizophrenia. Some of the tissues for these studies will be provided by the Alabama Brain Collection (ABC); a resource of the Departments'. Dr. Meador-Woodruff is Heman E. Drummond Professor & Chairman of the Department of Psychiatry, and Dr. McCullumsmith is the Director of Psychiatry's Adult Ambulatory Division.

Patients suffering from schizophrenia utilize more inpatient hospital beds than any other psychiatric or medical condition.



First Episode Clinic Offers Care to Patients after First Diagnosis

UAB Psychiatry's First Episode Schizophrenia Clinic was recently established to provide a comprehensive response to treat teen patients after first diagnosis. Early diagnosis and intervention facilitates prompt treatment, accelerated recovery, preservation of psychosocial skills, and decreased risk of relapse. The services offered are individually tailored to support the needs of the patient and his/her family. Services may include assessment, monitoring symptoms and recovery progress, medication management, and individualized treatment and educational plans focused on promoting family involvement and emotional support, as well as guidance to aid in the recovery process. The clinic

director, Adrienne Lahti, M.D., Professor & Division Director of Behavioral Neurobiology, noted that there are only a few of these clinics in the country and this is the only innovative schizophrenia clinic in Alabama dedicated to treating teens immediately after first diagnosis. There is growing evidence that schizophrenia can be managed better, and that complications associated with schizophrenia can be lessened. The facility was designed to provide supportive, warm, and personalized care to ease the burden of disease experienced by patients and their families; it is an innovative pathway to recovery, empowerment, and well-being. Dr. Lahti maintains that the management of schizophrenia is possible, and that complications associated with the diagnosis can be lessened if comprehensive treatment begins after the onset of symptoms and first diagnosis.

FUNDING THE FUTURE OF RESEARCH



In this issue of UAB Psychiatry, you've read about the growth of the newly formed UAB Mood Disorders program. Over the last few years, we have recruited several of the best and brightest clinicians and scientists in the United States for this program and other programs within the Department of Psychiatry. These recruits are leaders in the treatment and research of depression across the lifespan. These recruitments, and subsequent advancements in our program, would not have been possible without the support of philanthropic funds. Through generous gifts from members of our community, we were able to bring these innovative minds to UAB, to further add to our clinical and research base. These funds allow us to leap-frog research efforts, fund innovative ideas that can lead to NIH funding, and explore additional translational research paths.

In the last two years, the department has received commitments totaling \$2.9 million including a \$2.5 million gift to form the Bee McWane Reid Endowed Chair in Mood Disorders and the Bee McWane Reid Mood Disorders Research Fund. This endowed chair will be used to bring a nationally visible depression researcher to UAB, to further expand our growing mood disorders program. Our goal is to achieve a Top 10 ranking to become a leader in mood disorders

treatment and research efforts in the nation; however this will not be possible without philanthropic support from the community, university-wide collaboration efforts, and an outstanding clinical research team.

In order to achieve this goal, and to become a national leader in the area of mood disorders treatment and research, community support is crucial. Philanthropic support is needed for:

- Additional recruitment of nationally recognized scientists and physicians
- Seed funding for research acceleration to leapfrog novel research ideas, and leverage NIH funding
- Funds to groom our own rising stars by recruiting graduating residents to stay at UAB
- Accelerate ongoing research projects aimed at understanding the causes of and development of better treatment approaches for depression and bipolar disorder, and increased suicide prevention awareness

The vision for this program is that of a multidisciplinary, cross-campus program that provides diagnostic and consultative assessment, education programming, community outreach and partnership, and the development of cutting-edge research focused on understanding the causes of and development of better treatment approaches for depression and bipolar disorder.

Building on the department's current strengths in suicide awareness and prevention, laboratory models of depression, a strong group of preclinical research laboratories, and the rTMS (repetitive transcranial magnetic stimulation) program, we plan further growth and development of patient-based research which will include expansion of our programs in experimental therapeutics for mood disorders, neuromodulation, translational preclinical investigations, brain imaging in depression and bipolar disorder, pharmacogenomics, and mood disorders in children, adolescents, and the aged. With philanthropic support from the community, we will be well on our way to achieving our goal of becoming a Top 10 program.

WAYS TO PARTNER WITH PSYCHIATRY

Named Funds

Establishing an endowed fund named in your honor or that of a loved one is a wonderful way to join the fight against mental illness. A gift of \$25,000 or more establishes a fund which may be directed to specific research efforts, faculty support, recruitment efforts, or education of the next generation of physician-investigators. Multi-year pledges are a great way to establish a fund that will support the work of UAB Psychiatry for years to come.

Gifts of Stock and Appreciated Assets

Gifts of stock and appreciated assets to UAB have several advantages over cash gifts. In addition to the gratification of supporting a mission you believe in, the transfer of appreciated stock will provide increased tax benefits, giving more to UAB at less of a cost to you.

Planned Gifts

Planned gifts offer a great way to make a lasting impact. To extend your support for years to come, please consider a planned gift that can influence our research efforts and mission for many years, and offer you financial or tax benefits.

Outright gifts

To make an online gift, visit www.psychiatry.uab.edu and click on the "Give to Psychiatry" link at the top of the page. Alternatively, you can mail a check payable to the UAB Department of Psychiatry. Please note on the check if there is a specific area in the Department you would like the gift to be credited toward. Gifts should be mailed to: Eve Rhea, Director of Development, 1720 2nd Ave South, SC 560 Birmingham, Alabama 35294-0017

For more information about ways to partner with the Department of Psychiatry in our philanthropic efforts, please contact Eve Rhea at (205)975-7298 or erhea@uab.edu

ACCURACY, EFFECIENCY, AND CUSTOMER SERVICE: MEET PSYCHIATRY'S



Psychiatry's Access Department is not only a group of schedulers, but a separate team from the general UAB intake system that uses specialty-specific criteria to pair patients with appropriate providers. Another primary difference between the Access team and the UAB intake system is the fact that the Department provides all of the appropriate funds necessary to staff this team. Stephanie Perry, Patient Services Coordinator II and team leader for the Access Department, states "above all I feel that there is some mystery and confusion surrounding who we are and what it is we do. We have been called the "air traffic controllers" and "gatekeepers" by providing patients with resources and filling up physicians' schedules' as one would fill up a plane before takeoff." On average, the Access team receives around 400 phone calls per week screening each potential patient and scheduling for multiple clinics. All potential psychiatric outpatients must come through Access first before they can be seen by a UAB provider. These calls can range from providers to a patient in crisis. The Access team consists of three employees who use a rotating queue schedule to answer calls. Using this schedule, Access was able to raise incoming phone calls answered from 20% to 70% within six months. The Access Department not only schedules numerous types of appointments, but is able to refer patients to different providers around the Birmingham area. Stephanie compliments her team by contending "We are regularly exposed to many different types of demographics. In the world of mental health, you never know who will reach out for help. Accuracy, efficiency, and customer service is how we function together as a team."

“We have been called the
air traffic controllers and
gatekeepers...”

Publications by Theme:

Chronobiology

R. C. Besing, L. M. Hablitz, J. R. Paul, R. L. Johnson, R. A. Prosser, **K. L. Gamble**. Neuropeptide Y-induced phase shifts of PER2::LUC rhythms are mediated by long-term suppression of neuronal excitability in a phase-specific manner. *Chronobiology Int* 2012; 29: 91-102.

M. S. Bray, W. F. Ratcliffe, M. H. Grenett, R. A. Brewer, **K. L. Gamble**, M. E. Young. Quantitative analysis of light-phase restricted feeding reveals metabolic dyssynchrony in mice. *Int J Obes (Lond)* 2012.

M. P. DeAndrade, R. L. Johnson, Jr., E. L. Unger, L. Zhang, T. van Groen, **K. L. Gamble**, Y. Li. Motor restlessness, sleep disturbances, thermal sensory alterations and elevated serum iron levels in Btd9 mutant mice. *Hum Mol Genet* 2012; 21: 3984-3992.

A. H. Fargason, A. F. Hollar, S. White, **K. Gamble**. Adults With ADHD-Without Infomina History Have Subclinical Sleep Disturbance but Not Circadian Delay: **I. A. Kerman**, **S. M. Clinton**, D. N. Simpson, T. A. Bedrosian, R. Bernard, H. Akil, S. J. Watson. Inborn differences in environmental reactivity predict divergent diurnal behavioral, endocrine, and gene expression rhythms. *Psychoneuroendocrinology* 2012; 37: 256-269. An ADHD Phenotype? *J Atten Disord* 2012.

J. R. Paul, R. L. Johnson, **S. S. Jope**, **K. L. Gamble**. Disruption of circadian rhythmicity and suprachiasmatic action potential frequency in a mouse model with constitutive activation of glycogen synthase kinase 3. *Neuroscience* 2012; 226: 1-9.

G. X. Ruan, **K. L. Gamble**, M. L. Risner, L. A. Young, D. G. McMahon. Divergent roles of clock genes in retinal and suprachiasmatic nucleus circadian oscillators. *PLoS One* 2012; 7: e38985.

Community Psychiatry

Handbook of Community Psychiatry. H. L. McQuiston, W. E. Sowers, J. M. Ranz, **J. M. Feldman**, Eds., (Springer, New York, 2012).

R. M. Savage, J. M. Dillon, J. C. Hammel, T. C. Lewis, N. C. Johnson, L. M. Barlow, M. M. Brooms, P. M. Moore, H. E. Parker, K. Z. Rodney. The Alabama Coalition for a Healthier Black Belt: A Proof of Concept Project. *Community Mental Health J* 2012.

Psy B. J. Buck, L. K. Nolen, L. G. Koch, S. L. Britton, **I. A. Kerman**. Alterations in the brainstem preautonomic circuitry may contribute to hypertension associated with metabolic syndrome. In *Cardiovascular Risk Factors*, A. Y. Gasparian, Ed. (Intech, 2012).

Inflammation

M. S. Moehle, P. J. Webber, T. Tse, N. Sukar, D. G. Standaert, M. DeSilva, **R. M. Cowell**, A. B. West. LRRK2 inhibition attenuates microglial inflammatory responses. *J Neurosci* 2012; 32: 1602-1611.

H. Qin, W. I. Yeh, **P. De Sarno**, A. T. Holdbrooks, Y. Liu, M. T. Muldowney, S. L. Reynolds, L. D. Yanagisawa, T. H. Fox, 3rd, K. Park, K. E. Harrington, C. Raman, E. N. Benveniste. Signal transducer and activator of transcription-3/suppressor of cytokine signaling-3 (STAT3/SOCS3) axis in myeloid cells regulates neuroinflammation. *Proc Natl Acad Sci U S A* 2012; 109: 5004-5009.

C. M. Sestero, D. J. McGuire, **P. De Sarno**, E. C. Brantley, G. Soldevila, R. A. Axtell, C. Raman. CD5-dependent CK2 activation pathway regulates threshold for T cell anergy. *J Immunol* 2012; 189: 2918-2930.

Molecular Neuroscience

S. Gundemir, G. Colak, **J. Tucholski**, G. V. Johnson. Transglutaminase 2: a molecular Swiss army knife. *Biochim Biophys Acta* 2012; 1823: 406-419.

E. K. Lucas, S. E. Dougherty, L. J. McMeekin, C. A. Trinh, C. S. Reid, **R. M. Cowell**. Developmental alterations in motor coordination and medium spiny neuron markers in mice lacking pgc-1alpha. *PLoS One* 2012; 7: e42878.

L. A. McCollum, J. K. Roche, **R. C. Roberts**. Immunohistochemical localization of enkephalin in the human striatum: a postmortem ultrastructural study. *Synapse* 2012; 66: 204-219.

M. Melendez-Ferro, M. W. Rice, **R. C. Roberts**, **E. Perez-Costas**. Dual use of immunohistochemistry for film densitometry and light microscopy. *J Neurosci Methods* 2012;

208: 86-91.

M. W. Rice, **R. C. Roberts**, **M. Melendez-Ferro**, **E. Perez-Costas**. Neurochemical characterization of the tree shrew dorsal striatum. *Front Neuroanat* 2011; 5: 53.

R. K. Simmons, J. L. Howard, D. N. Simpson, H. Akil, **S. M. Clinton**. DNA methylation in the developing hippocampus and amygdala of anxiety-prone versus risk-taking rats. *Dev Neurosci* 2012; 34: 58-67.

W. Zhou, L. Chen, J. Paul, S. Yang, F. Li, K. Sampson, J. R. Woodgett, J. M. Beaulieu, **K. L. Gamble**, X. Li. The effects of glycogen synthase kinase-3beta in serotonin neurons. *PLoS One* 2012; 7: e43262.

Mood Disorders

M. J. Garcia-Fuster, G. S. Parks, **S. M. Clinton**, S. J. Watson, H. Akil, O. Civelli. The melanin-concentrating hormone (MCH) system in an animal model of depression-like behavior. *Eur Neuropharmacol* 2012; 22: 607-613.

S. A. Gibson, Z. Korade, **R. C. Shelton**. Oxidative stress and glutathione response in tissue cultures from persons with major depression. *J Psychiatr Res* 2012; 46: 1326-1332.

R. M. Hayes, P. Wu, **R. C. Shelton**, W. O. Cooper, W. D. Dupont, E. Mitchell, T. V. Hartert. Maternal antidepressant use and adverse outcomes: a cohort study of 228,876 pregnancies. *Am J Obstet Gynecol* 2012; 207: 49 e41-49.

I. A. Kerman. New insights into BDNF signaling: relevance to major depression and antidepressant action. *Am J Psychiatry* 2012; 169: 1137-1140.

I. A. Kerman, R. Bernard, W. E. Bunney, E. G. Jones, A. F. Schatzberg, R. M. Myers, J. D. Barchas, H. Akil, S. J. Watson, R. C. Thompson. Evidence for transcriptional factor dysregulation in the dorsal raphe nucleus of patients with major depressive disorder. *Front Neurosci* 2012; 6: 135.

A. A. Nierenberg, C. Katsky, B. P. Brennan, **R. C. Shelton**, R. Perlis, D. V. Iosifescu. Mitochondrial modulators for bipolar disorder: A pathophysiologically informed paradigm for new drug development. *Aust N Z J Psychiatry* 2012.

R. C. Shelton. Does concomitant use of NSAIDs reduce the effectiveness of antidepressants? *Am J Psychiatry* 2012; 169: 1012-1015.

M. T. Treadway, N. A. Bossaller, **R. C. Shelton**, D. H. Zald. Effort-based decision-making in major depressive disorder: a translational model of motivational anhedonia. *J Abnorm Psychol* 2012; 121: 553-558.

C. A. Webb, R. J. Derubeis, S. Dimidjian, S. D. Hollon, J. D. Amsterdam, **R. C. Shelton**. Predictors of patient cognitive therapy skills and symptom change in two randomized clinical trials: the role of therapist adherence and the therapeutic alliance. *J Consult Clin Psychol* 2012; 80: 373-381.

Neurodegeneration Disorders

Kumar, A. Kneynsberg, **J. Tucholski**, G. Perry, T. van Groen, P. J. Dettliff, **M. Lesort**. Tissue transglutaminase overexpression does not modify the disease phenotype of the R6/2 mouse model of Huntington's disease. *Exp Neurol* 2012; 237: 78-89.

Psychosomatic Medicine

R. A. Epstein, W. V. Bobo, **R. C. Shelton**, P. G. Arbogast, J. A. Morrow, W. Wang, R. Chandrasekhar, W. O. Cooper. Increasing use of atypical antipsychotics and anticonvulsants during pregnancy. *Pharmacoepidemiol Drug Saf* 2012.

M. S. Kozak, M. J. Mugavero, J. Ye, I. Aban, S. T. Lawrence, C. R. Nevin, J. L. Raper, **C. McCullumsmith**, J. E. Schumacher, H. M. Crane, M. M. Kitahata, M. S. Saag, J. H. Willig. Patient reported outcomes in routine care: advancing data capture for HIV cohort research. *Clin Infect Dis* 2012; 54: 141-147.

B. D. Rapkin, E. S. Weiss, D. W. Lounsbury, H. S. Thompson, R. M. Goodman, C. B. Schechter, C. Merzel, **R. C. Shelton**, A. E. Blank, J. Erb-Downward, A. Williams, P. Valera, D. K. Padgett. Using the Interactive Systems Framework to Support a Quality Improvement Approach to Dissemination of Evidence-Based Strategies to Promote Early Detection of Breast Cancer: Planning a Comprehensive Dynamic Trial. *Am J Community Psychol* 2012.

J. E. Schumacher, **C. McCullumsmith**, M. J. Mugavero, P. E. Ingle-Pang, J. L. Raper, J. H. Willig, Z. You, D. S. Batey, H. Crane, S. T. Lawrence, C. Wright, G. Treisman, M. S. Saag. Routine Depression Screening in an HIV Clinic Cohort Identifies Patients with Complex Psychiatric Co-morbidities Who Show Significant Response to Treatment. *AIDS Behav* 2012.

J. R. Sly, T. Edwards, **R. C. Shelton**, L. Jandorf. Identifying Barriers to Colonoscopy Screening for Nonadherent African American Participants in a Patient Navigation Intervention. *Health Educ Behav* 2012.

A. M. Watson, K. M. Prasad, L. Klei, J. A. Wood, R. H. Yolken, R. C. Gur, L. D. Bradford, M. E. Calkins, J. Richard, N. Edwards, **R. M. Savage**, T. B. Allen, J. Kwentus, J. P. McEvoy, A. B. Santos, H. W. Wiener, R. C. Go, R. T. Perry, H. A. Nasrallah, R. E. Gur, B. Devlin, V. L. Nimgaonkar. Persistent infection with neurotropic herpes viruses and cognitive impairment. *Psychol Med* 2012; 1-9.

Schizophrenia:

M. Barme, J. Wood, K. Chowdari, A. M. Watson, C. Celik, H. Mansour, L. Klei, R. C. Gur, L. D. Bradford, M. E. Calkins, A. B. Santos, N. Edwards, J. Kwentus, J. P. McEvoy, T. B. Allen, **R. M. Savage**, H. A. Nasrallah, R. E. Gur, R. T. Perry, R. C. Go, B. Devlin, R. Yolken, V. L. Nimgaonkar. Evaluation of HLA Polymorphisms in Relation to Schizophrenia Risk and Infectious Exposure. *Schizophr Bull* 2012; 38: 1149-1154.

M. S. Bolding, **A. C. Lahti**, T. J. Gawne, K. B. Hopkins, D. Gurler, P. D. Gamlin. Ocular convergence deficits in schizophrenia. *Front Psychiatry* 2012; 3: 86.

M. S. Bolding, M. A. Reid, K. B. Avars, **R. C. Roberts**, P. D. Gamlin, T. J. Gawne, D. M. White, J. A. den Hollander, **A. C. Lahti**. Magnetic Transfer Contrast Accurately Localizes Substantia Nigra Confirmed by Histology. *Biol Psychiatry* 2012.

S. E. Dougherty, J. L. Reeves, E. K. Lucas, **K. L. Gamble**, **M. Lesort**, **R. M. Cowell**. Disruption of Purkinje cell function prior to huntington accumulation and cell loss in an animal model of Huntington disease. *Exp Neurol* 2012; 237: 171-178.

J. B. Drummond, M. Simmons, V. Haroutunian, **J. H. Meador-Woodruff**. Upregulation of cornichon transcripts in the dorsolateral prefrontal cortex in schizophrenia. *Neuroreport* 2012; 23: 1031-1034.

A. J. Funk, **R. E. McCullumsmith**, V. Haroutunian, **J. H. Meador-Woodruff**. Abnormal activity of the MAPK- and cAMP-associated signaling pathways in frontal cortical areas in postmortem brain in schizophrenia. *Neuropsychopharmacology* 2012; 37: 896-905.

J. C. Hammond, J. H. Meador-Woodruff, V. Haroutunian, **R. E. McCullumsmith**. AMPA receptor subunit expression in the endoplasmic reticulum in frontal cortex of elderly patients with schizophrenia. *PLoS One* 2012; 7: e39190.

N. V. Kraguljac, M. Reid, D. White, R. Jones, J. den Hollander, D. Lowman, **A. C. Lahti**. Neurometabolites in schizophrenia and bipolar disorder - A systematic review and meta-analysis. *Psychiatry Res* 2012; 203: 111-125.

N. V. Kraguljac, M. A. Reid, D. M. White, J. den Hollander, **A. C. Lahti**. Regional Decoupling of N-acetyl-aspartate and Glutamate in Schizophrenia. *Neuropsychopharmacology* 2012; 37: 2635-2642.

R. E. McCullumsmith, J. Hammond, A. Funk, **J. H. Meador-Woodruff**. Recent advances in targeting the ionotropic glutamate receptors in treating schizophrenia. *Curr Pharm Biotechnol* 2012; 13: 1535-1542.

M. S. Moehle, R. F. Ludeña, V. Haroutunian, **J. H. Meador-Woodruff**, **R. E. McCullumsmith**. Regional differences in expression of beta-tubulin isoforms in schizophrenia. *Schizophr Res* 2012; 135: 161-166.

E. Perez-Costas, **M. Melendez-Ferro**, M. W. Rice, R. R. Conley, **R. C. Roberts**. Dopamine pathology in schizophrenia: analysis of total and phosphorylated tyrosine hydroxylase in the substantia nigra. *Front Psychiatry* 2012; 3:

M. D. Rubio, J. B. Drummond, **J. H. Meador-Woodruff**. Glutamate receptor abnormalities in Schizophrenia: Implications for innovative treatments. *Biomol Ther* 2012; 20: 1-18.

M. D. Rubio, V. Haroutunian, **J. H. Meador-Woodruff**. Abnormalities of the Duo/Ras-related C3 botulinum toxin substrate 1/p21-activated kinase 1 pathway drive myosin light chain phosphorylation in frontal cortex in schizophrenia. *Biol Psychiatry* 2012; 71: 906-914.

R. M. Savage, H. W. Wiener, V. Nimgaonkar, B. Devlin, M. E. Calkins, R. E. Gur, J. O'Jile, L. D. Bradford, N. Edwards, J. Kwentus, T. Allen, J. P. McEvoy, H. Nasrallah, A. B. Santos, T. Aduraja, **A. Lahti**, R. S. May, L. Montgomery-Barefield, R. C. Go. Heritability of functioning in families with schizophrenia in relation to neurocognition. *Schizophr Res* 2012; 139: 105-109.

D. Shan, V. Haroutunian, **J. H. Meador-Woodruff**, **R. E. McCullumsmith**. Expression of equilibrative nucleoside transporter type 1 protein in elderly patients with schizophrenia. *Neuroreport* 2012; 23: 224-227.

S. M. Somerville, R. R. Conley, **R. C. Roberts**. Striatal mitochondria in subjects with chronic undifferentiated vs. chronic paranoid schizophrenia. *Synapse* 2012; 66: 29-41.

H. Wiener, L. Klei, M. Calkins, J. Wood, V. Niringaonkar, R. Gur, L. D. Bradford, J. Richard, N. Edwards, **R. Savage**, J. Kwentus, T. Allen, J. McEvoy, A. Santos, B. Devlin, R. Go. Principal Components of Heritability From Neurocognitive Domains

Differ Between Families With Schizophrenia and Control Subjects. *Schizophr Bull* 2012.

Substance Abuse

B. C. Clark, A. Perkins, **C. B. McCullumsmith**, A. M. Islam, J. Sung, **K. L. Cropsey**. What Does Self-identified Drug of Choice Tell Us About Individuals Under Community Corrections Supervision? *J Addict Med* 2012; 6: 57-67.

S. M. Clinton, C. A. Turner, S. B. Flagel, D. N. Simpson, S. J. Watson, H. Akil. Neonatal fibroblast growth factor treatment enhances cocaine sensitization. *Pharmacol Biochem Behav* 2012; 103: 6-17.

Suicide

G. N. Pandey, H. S. Rizavi, X. Ren, J. Fareed, D. A. Hopensteadt, **R. C. Roberts**, R. R. Conley, Y. Dwivedi. Proinflammatory cytokines in the prefrontal cortex of teenage suicide victims. *J Psychiatr Res* 2012; 46: 57-63.

Violence

C. B. Clark, A. Perkins, **C. B. McCullumsmith**, M. A. Islam, E. E. Hanover, **K. L. Cropsey**. Characteristics of victims of sexual abuse by gender and race in a community corrections population. *J Interpers Violence* 2012; 27: 1844-1861.

INVESTIGATOR

Sarah Clinton
Rita Cowell

SPONSOR

National Institute of Mental Health/NIH/DHHS.....
National Institute of Neurological Disorders and Stroke/NIH/DHHS.....
Tourette Syndrome Association, Inc.....

Karen L. Cropsey
James T. Cullinan

National Cancer Institute/NIH/DHHS.....
Pfizer Pharmaceuticals.....

Pfizer Pharmaceuticals.....

Patrizia De Samo
Rachel E. Fargason

National Institute of Neurological Disorders and Stroke/NIH/DHHS.....
OTSUKA PHARMACEUTICAL DEVELOPMENT & COMMERCIALIZATION, INC.....

Karen L. Gamble
Ilan Kerman

TAKEDA PHARMACEUTICALS NORTH AMERICA, INC.....
National Institute of General Medical Sciences/NIH/DHHS.....
National Alliance for Research on Schizophrenia and Depression.....

Cleveland F. Kinney

National Institute of Mental Health/NIH/DHHS.....
JANSSEN AI R&D.....

JANSSEN AI R&D.....

WYETH PHARMACEUTICALS, INC.....

Adrienne C. Lahti

National Institute of Mental Health/NIH/DHHS.....
ORTHO-MCNEIL, INC.....

Cheryl McCullumsmith

UNIVERSITY OF ALABAMA HEALTH SERVICES FOUNDATION.....

Robert E.
McCullumsmith

Duke (Doris) Charitable Foundation.....
National Institute of Mental Health/NIH/DHHS.....
National Institute of Mental Health/NIH/DHHS.....
National Institute of Mental Health/NIH/DHHS.....

Roberta May

ORTHO-MCNEIL, INC.....

James Meador-
Woodruff

National Institute of Mental Health/NIH/DHHS.....

Miguel Melendez-Ferro

National Institute of Mental Health/NIH/DHHS.....

Robert M. Savage

National Institute of Mental Health/NIH/DHHS.....

Richard C. Shelton

JANSSEN RESEARCH & DEVELOPMENT, LLC.....

JANSSEN RESEARCH & DEVELOPMENT, LLC.....

MASSACHUSETTS GENERAL HOSPITAL.....

National Institutes of Health/DHHS.....

NAUREX, INC.....

TAKEDA GLOBAL RESEARCH & DEVELOPMENT CENTER.....

TAKEDA GLOBAL RESEARCH & DEVELOPMENT CENTER.....

PROJECT TITLE

Neurodevelopmental Underpinnings of Rodent Anxiety and Depressive Behavior
PGC-1alpha and GABAergic Dysfunction in Huntington Disease
The Impact of Early Postnatal Hypoxia on the Transcriptional Regulation of Basal Ganglia Development
Integrated Smoking Cessation Treatment for Low Income Community Corrections
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study To Evaluate the Efficacy, Safety and Tolerability of Desvenlafaxine Succinate Sustained-Release (DVS SR) in the Treatment of Children and Adolescent Outpatients with Major Depressive Disorder
A 6 Month, Open-Label, Multi-Center, Flexible-Dose Extension Study to the B2061032 Study to Evaluate the Safety, Tolerability and Efficacy of Desvenlafaxine Succinate Sustained-Release (DVS SR) Tablets in the Treatment of Children and Adolescent Outpatients with Major Depressive Disorder
GSK3: Immunoregulator in Experimental Autoimmune Encephalomyelitis (EAE)
A Phase 2, Multicenter, Open-Label Study to Assess the Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adult Patients with Major Depressive Disorder
Ramelteon for the Treatment of Adult Patients with ADHD Related Insomnia
Integration of Photic and Nonphotic Signaling in the Circadian Pacemaker
Alterations of Brainstem Structure and Gene Expression in Depression: Relevance to Chronic Pain Comorbidity
Neural Substrates of Somatomotor and Autonomic Disturbances in Major Depression
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in Patients with Mild to Moderate Alzheimer's Disease who are Apolipoprotein E4 Carriers
A Phase 3 Extension, Multicenter, Double-Blind, Long Term Safety and Tolerability Treatment Trial of Bapineuzumab (AAB 001, ELN115727) in Subjects with Alzheimer's Disease who Participated in Study ELN115727-301 or in Study ELN115727-302
A Phase 3 Extension, Multicenter, Long-Term Safety and Tolerability Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects with Alzheimer Disease Who are Apolipoprotein E4 Carriers and Participated in Study 3133K1-3001-US
Treatment Response in Schizophrenia: Bridging Imaging and Postmortem Studies
Treatment Response in Schizophrenia Bridging Imaging and Postmortem Studies
Screening and Brief Treatment for Substance Abuse Disorders in the Emergency Department
Abnormalities of Glutamate Transporter Localization in Schizophrenia
AMPA Receptor Trafficking in Schizophrenia
Defects of Subcellular Glutamate Transporter Localization in Schizophrenia
Abnormalities of Glutamate Transporter Localization in Schizophrenia
Validation Study of InterSePT Scale for Suicidal Thinking-Plus (ISST-Plus), Sheehan Suicide Tracking Scale (S-STS) and Columbia Suicide Severity Rating Scale (C-SSRS); Consistency of Mapping to Columbia Classification Algorithm of Suicide Assessment (C-CASA)
Schizophrenia as a Disorder of Glutamate Receptor Trafficking
Neuropathology of Dopamine Systems in Schizophrenia
2/4-A Genomic Approach to Schizophrenia
A Double-Blind, Randomized, Placebo-Controlled, Parallel Group Dose Frequency Study of Ketamine in Subjects with Treatment-Resistant Depression
Paliperidone and Lithium in the Treatment of Suicidality - Treatment Indication and Epigenetic Regulation
Comparative Effectiveness of a Second Generation Antipsychotic Mood Stabilizer and a Classic Mood Stabilizer for Bipolar Disorder
2/2- Ziprasidone Augmentation of SSRIs for Treatment-Resistant Depression
Phase 2, Double-Blind, Placebo-Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects with Inadequate/Partial Response to Antidepressants during the Current Episode of Major Depressive Disorder
A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept, Phase 2 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 (Ramelteon) Tablet for Sublingual Administration (TAK-375SL Tablet) 0.1 mg, and 0.8 mg in the Treatment of Acute Depressive Episodes Associated with Bipolar I Disorder in Adult Patients who are on Lithium and/or Valproate
A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept, Phase 2 Study to Evaluate the Efficacy and Safety of Once a Day TAK-375SL 0.1, 0.4, and 0.8 mg as an Adjunctive Therapy to Treatment-as-Usual in the Maintenance Treatment of Bipolar I Disorder in Adult Patients

Psychiatry

SC 560
1530 3rd Avenue South
Birmingham, AL 35294-0017

Mail Panel



Today's Promise...
tomorrow's breakthroughs

Create your legacy for the UAB Department of Psychiatry
Visit our website at www.uab.edu/plannedgiving
or contact Elizabeth A. Ponder at (205) 934-0759 or eponder@uab.edu